zip >>> 94901
sector >>> Healthcare
fullTimeEmployees >>> 3001
longBusinessSummary >>> BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide, a peptide therapeutic that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; and BMN 307, an AAV5 mediated gene therapy to normalize blood phenylalanine concentration levels in patients with phenylketonuria. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd.; and a preclinical collaboration and license agreement with DiNAQOR AG for the development of gene therapies to treat rare genetic cardiomyopathies. The company was founded in 1996 and is headquartered in San Rafael, California.
city >>> San Rafael
phone >>> 415 506 6700
state >>> CA
country >>> United States
companyOfficers >>> []
website >>> http://www.biomarin.com
maxAge >>> 1
address1 >>> 770 Lindaro Street
industry >>> Biotechnology
previousClose >>> 85.77
regularMarketOpen >>> 87.01
twoHundredDayAverage >>> 89.28175
trailingAnnualDividendYield >>> None
payoutRatio >>> 0
volume24Hr >>> None
regularMarketDayHigh >>> 88.75
navPrice >>> None
averageDailyVolume10Day >>> 2208316
totalAssets >>> None
regularMarketPreviousClose >>> 85.77
fiftyDayAverage >>> 84.27242
trailingAnnualDividendRate >>> None
open >>> 87.01
averageVolume10days >>> 2208316
expireDate >>> None
yield >>> None
algorithm >>> None
dividendRate >>> None
exDividendDate >>> None
beta >>> 0.71271
circulatingSupply >>> None
startDate >>> None
regularMarketDayLow >>> 86.52
priceHint >>> 2
currency >>> USD
trailingPE >>> 19.296053
regularMarketVolume >>> 1093775
lastMarket >>> None
maxSupply >>> None
openInterest >>> None
marketCap >>> 15972824064
volumeAllCurrencies >>> None
strikePrice >>> None
averageVolume >>> 1518870
priceToSalesTrailing12Months >>> 8.574719
dayLow >>> 86.52
ask >>> 87.96
ytdReturn >>> None
askSize >>> 800
volume >>> 1093775
fiftyTwoWeekHigh >>> 131.95
forwardPE >>> 1257
fromCurrency >>> None
fiveYearAvgDividendYield >>> None
fiftyTwoWeekLow >>> 68.25
bid >>> 85.51
tradeable >>> False
dividendYield >>> None
bidSize >>> 800
dayHigh >>> 88.75
exchange >>> NMS
shortName >>> BioMarin Pharmaceutical Inc.
longName >>> BioMarin Pharmaceutical Inc.
exchangeTimezoneName >>> America/New_York
exchangeTimezoneShortName >>> EST
isEsgPopulated >>> True
gmtOffSetMilliseconds >>> -18000000
underlyingSymbol >>> None
quoteType >>> EQUITY
symbol >>> BMRN
underlyingExchangeSymbol >>> None
headSymbol >>> None
messageBoardId >>> finmb_25605
uuid >>> bcd60339-c59b-3a43-af89-b10253407aca
market >>> us_market
annualHoldingsTurnover >>> None
enterpriseToRevenue >>> 8.358
beta3Year >>> None
profitMargins >>> 0.45738998
enterpriseToEbitda >>> 443.736
52WeekChange >>> None
morningStarRiskRating >>> None
forwardEps >>> 0.07
revenueQuarterlyGrowth >>> None
sharesOutstanding >>> 181530000
fundInceptionDate >>> None
annualReportExpenseRatio >>> None
bookValue >>> 22.336
sharesShort >>> 11185475
sharesPercentSharesOut >>> 0.0616
fundFamily >>> None
lastFiscalYearEnd >>> 1577750400
heldPercentInstitutions >>> 1.00247
netIncomeToCommon >>> 852025024
trailingEps >>> 4.56
lastDividendValue >>> None
SandP52WeekChange >>> None
priceToBook >>> 3.9393802
heldPercentInsiders >>> 0.00611
nextFiscalYearEnd >>> 1640908800
mostRecentQuarter >>> 1601424000
shortRatio >>> 7.15
sharesShortPreviousMonthDate >>> 1606694400
floatShares >>> 180244437
enterpriseValue >>> 15568911360
threeYearAverageReturn >>> None
lastSplitDate >>> None
lastSplitFactor >>> None
legalType >>> None
morningStarOverallRating >>> None
earningsQuarterlyGrowth >>> 13.26
dateShortInterest >>> 1609372800
pegRatio >>> 0.43
lastCapGain >>> None
shortPercentOfFloat >>> 0.0705
sharesShortPriorMonth >>> 11869326
category >>> None
fiveYearAverageReturn >>> None
regularMarketPrice >>> 87.01
logo_url >>> https://logo.clearbit.com/biomarin.com
